Pheiron is an applied AI lab dedicated to Biological Alpha: the ability to know what biology will work in humans early enough to change the outcome of a drug program. We underwrite biology risk against clinical outcomes and use the edge to select and develop drug programs with the highest probability of success. At today's pace, humanity will wait 500 years for every known disease to have a cure. Twenty generations of patients. Pheiron compresses this timeline by radically increasing the drug-per-dollar output. 500 years is too long. We publish predictions on selected upcoming clinical readouts to validate our models. Backed by Ananda, Compound, Fusion Fund and Hummingbird. → pheiron.com
| Website | http://pheiron.com |
| Employees | 12 (10 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | Drug Development, Drug Discovery, Evidence Based Medicine, Clinical Trials, Biomarker Discovery, Clinical Research, Clinical Development, Precision Medicine, Target Validation, Target Identification, Pharmaceutical Research, Translational Medicine, Biotechnology |
| Competitors | Veeva Systems, Medidata Solutions, Oracle, Dassault Systèmes, IQVIA, Synarc, Parexel, Covance, ClinicalResearch.com, CRF Health +37 more (view full list) |
Looking for a particular Pheiron employee's phone or email?
Thore Buergel is the Co-Founder and CEO of Pheiron.
10 people are employed at Pheiron.